Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Erding – page 63

1 344 clinical trials in Erding, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Erding at a glance
1 344
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 344 trials in Erding

Open in trial search

Study on OM-85 for Preventing Respiratory Infections in Children with Wheezing Illness (Ages 6 Months to 5 Years)

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years
  • Sponsor:OM Pharma SA

Evaluating Higher Dose Nusinersen in Patients with Spinal Muscular Atrophy Previously Treated with Risdiplam

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Nusinersen
  • Sponsor:Biogen Idec Research Limited

Study of Tepotinib and Osimertinib for Patients with Advanced or Metastatic Lung Cancer Resistant to Osimertinib Therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Osimertinib
  • Sponsor:Merck Healthcare KGaA

B-cell lymphoma

Not recruiting

Study on Rituximab and Drug Combination for Treating Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Abiraterone Acetate
  • Sponsor:Universitaetsklinikum Muenster AöR

Hodgkin's disease

Not recruiting

Study of Tislelizumab, Dacarbazine, Vinblastine Sulfate, and Doxorubicin Hydrochloride for Adults with Early-Stage Unfavorable Hodgkin Lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dacarbazine
  • Sponsor:University Of Cologne

IgA nephropathy

Not recruiting

Study on the Effects of Atacicept in Adults with IgA Nephropathy

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atacicept
  • Sponsor:Vera Therapeutics Inc.

Study on Allogeneic Stem Cell Transplantation for Children and Adolescents with Acute Lymphoblastic Leukemia Using Etoposide, Treosulfan, and Thiotepa

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Blinatumomab
  • Sponsor:St. Anna Childrens Cancer Research Institute GmbH

Hepatic cirrhosis

Not recruiting

Study on Zibotentan and Dapagliflozin for Patients with Liver Cirrhosis and Portal Hypertension

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin
  • Sponsor:AstraZeneca AB

Hidradenitis

Not recruiting

A study to evaluate the effectiveness and safety of BFB759 in adults with moderate to severe hidradenitis suppurativa

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BFB759
  • Sponsor:Bluefin Biomedicine Inc.

Migraine without aura

Not recruiting

Pharmacokinetics, Pharmacodynamics and Safety of Inhaled and Intravenous d,l‑lysine acetylsalicylate in Healthy Adults with Migraine

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · Healthy volunteers
  • Substances:D,L-Lysine Acetylsalicylate
  • Sponsor:Aspiair GmbH

Study of S227928 Alone and with Venetoclax for Patients with Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Allopurinol
  • Sponsor:Institut De Recherches Internationales Servier IRIS

Crohn's disease

Not recruiting

Study on Guselkumab for Patients with Moderate to Severe Crohn's Disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Guselkumab
  • Sponsor:Janssen Cilag International

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Erding

What the registry says about research in the country

01 Hematologic Disorders

Innovative research focusing on Myelodysplastic Syndrome (MDS), comparing novel therapeutic approaches for patients with lower-risk conditions. The studies aim to evaluate treatment effectiveness in managing blood cell production disorders.

  • Lower-risk MDS management
  • Blood cell production therapy
  • Treatment conversion studies

Current trials are investigating comparative effectiveness of different therapeutic agents in managing transfusion dependency.

02 Blood Disorders

Advanced research into polycythemia vera treatment resistance, utilizing artificial intelligence to predict treatment outcomes. Studies focus on understanding hydroxyurea resistance patterns in affected patients.

  • Treatment resistance evaluation
  • AI-driven predictions
  • Therapeutic monitoring

Research combines traditional clinical approaches with modern machine learning techniques to optimize treatment strategies.

03 Cardiovascular Medicine

Groundbreaking research on acute coronary syndrome and atrial fibrillation, exploring optimized antiplatelet therapy protocols. Studies evaluate new approaches for patients undergoing percutaneous coronary intervention.

  • Antiplatelet therapy optimization
  • Cardiac intervention outcomes
  • Bleeding risk management

Investigations focus on balancing therapeutic efficacy with safety in complex cardiac conditions.

04 Advanced Myelofibrosis

Clinical investigations of intermediate and high-risk myelofibrosis, exploring combination therapies and novel treatment approaches. Research aims to establish optimal dosing strategies for enhanced patient outcomes.

  • Combination therapy assessment
  • Treatment tolerability studies
  • Dose optimization research

Studies focus on developing safer and more effective treatment protocols for advanced stages of the disease.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.